Meropenem Agmed (Meropenem)

Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, which blocks the final step of peptidoglycan cross‑linking. This leads to weakened cell walls, osmotic instability and ultimately bacterial lysis. Its broad affinity for multiple PBPs and resistance to many β‑lactamases give it activity against a wide range of Gram‑negative, Gram‑positive and anaerobic bacteria.

The dosing regimen for Meropenem Agmed is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function and local antimicrobial guidelines. No fixed dose is provided here; the prescriber will calculate the appropriate intravenous infusion rate and duration for each individual case.

Meropenem is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy only if the potential benefit justifies any potential risk. Limited data are available for breastfeeding; the decision should be made by the healthcare provider after weighing benefits and risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After receiving the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Meropenem shares the carbapenem class’s broad‑spectrum activity and β‑lactamase stability, but it has a slightly lower affinity for certain Pseudomonas aeruginosa strains compared with imipenem‑cilastatin. It is often preferred for infections where a lower risk of nephrotoxicity is desired, as it does not require co‑administration of a renal protective agent. Clinical choice depends on local resistance patterns and patient-specific factors.

Meropenem Agmed for injection must be stored at 2‑8 °C (refrigerated). Keep the vials in the original packaging, protect them from light, and do not freeze or shake the solution. Once reconstituted, use the preparation within the time frame recommended by the manufacturer and discard any unused portion.

Meropenem Agmed is given as an intravenous infusion. The solution is prepared by reconstituting the powder with the appropriate diluent, then administered over a period specified by the prescriber, typically 15‑30 minutes. Infusion rates may be adjusted for patients with renal impairment or for specific infection sites.

The most serious adverse events include seizures, especially in patients with pre‑existing central nervous system disorders or when high doses are used, and severe hypersensitivity reactions such as anaphylaxis. Additionally, Clostridioides difficile‑associated colitis can occur, and renal or hepatic dysfunction may worsen in susceptible individuals. Prompt medical evaluation is required if any of these events arise.

Meropenem Agmed is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Caution is also advised for patients with a history of seizures, severe renal impairment (unless dose‑adjusted), or those receiving concomitant drugs that lower the seizure threshold.